ALK and non-small cell lung carcinoma: Moreover, the second generation of ALK-TKIs showed a high activity in NSCLC patients with distant metastases, especially in central nervous system (CNS) metastases which may extend treatment possibilities in advanced stages of NSCLC [5–7].